Notice of Special Interest (NOSI): Examining Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Heart, Lung, Blood, and Sleep Function
https://grants.nih.gov/grants/guide/notice-files/NOT-HL-21-025.html
november 24, 2021pa-20-183 - nih research project grant (parent r01 clinical trial required) pa-20-185 - nih research project grant (parent r01 clinical trial not allowed) not-hl-19-690 - nhlbi limitations on clinical trial applications submitted to the nih parent (r01 clinical trial required) funding opportunity announcement (foa)national heart, lung, and blood institute (nhlbi)purposethe purpose of this notice of special interest (nosi) is to stimulate research focused on elucidating the impact of hiv pre-exposure prophylaxis (prep) on heart, lung, blood, and sleep (hlbs) conditions. projects ranging from basic mechanistic studies to implementation investigations, including clinical studies and nih-defined clinical trials fitting the definition of mechanistic clinical trials/besh research, may be considered responsive to the notice.backgroundthe landscape of hiv management changed significantly with the demonstration (via multiple nih-funded clinical trials) that specific antiretroviral therapies used in the treatment of hiv could also be employed in uninfected, at-risk individuals prior to hiv exposure to prevent infection. this strategy is known as pre-exposure prophylaxis (prep). it is sufficiently effective that the world health organization began recommending prep to at-risk individuals in 2015 as part of its guidelines for prevention of hiv. the cdc estimated that in 2015, 1.1 million americans had an indication for prep (see https://pubmed.ncbi.nlm.nih.gov/29941379/ for details), and prep is a key feature of the 10-year ending the hiv epidemic initiative announced in 2019.though the benefits of prep for reducing transmission of hiv are well established, the long-term effects of these drugs on the manifestations of hlbs conditions in individuals who are at-risk but not infected with hiv are relatively unstudied. use of these agents chronically by individuals who do not have hiv (and thus are not at direct risk for the hlbs sequelae of hiv infection itself) may uncover unexpected effects, positive or negative. this nosi is intended to stimulate research into identifying these potentially unexpected effects, so that the efficacy and impact of prep can be maximized by enhancing unforeseen positive effects on hlbs conditions and by minimizing potential unforeseen negative effects.research objectives and examplesthis nosi is intended to stimulate studies of the effects of prep on hlbs function/disease at all levels. specific examples of the kinds of questions/studies appropriate for this nosi are presented by broad category below and include, but are not limited to, the following:interests across the research spectrummolecular/cellular examplestranslational/clinical examplesepidemiologic/implementation/”big data” & informatics examplestypes of studies that would not be considered responsive to this nosi include, but are not limited to:application and submission informationsubmit applications for this initiative using one of the following funding opportunity announcements (foas) or any reissues of these announcement through the expiration date of this notice. note that aids application due dates are being used for this nosi.all instructions in the sf424 (r&r) application guide and the funding opportunity announcement used for submission must be followed, with the following additions:applications nonresponsive to terms of this nosi will not be considered for the nosi initiative.scientific/research contact(s)josh fessel, md, phd nhlbi, division of lung diseases telephone: 301-827-5514 email: josh.fessel@nih.govshimian zou, ph.d. nhlbi hiv/aids coordinator; epidemiology; transfusion telephone: 301-435-0065 email: shimian.zou@nih.govpeer review contact(s)examine your era commons account for review assignment and contact information (information appears two weeks after the submission due date).financial/grants management contact(s)anthony agresti national heart, lung, and blood institute (nhlbi) telephone: 301-827-8014 email: agrestia@nhlbi.nih.govweekly toc for this announcement nih funding opportunities and noticesnote: for help accessing pdf, rtf, ms word, excel, powerpoint, audio or video files, see help downloading files.